The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Incidence patterns and clinical implications of venous thromboembolisms (VTE) in patients (p) with neuroendocrine tumors (NET).
 
Jorge Hernando
No Relationships to Disclose
 
Maria Roca
No Relationships to Disclose
 
Alejandro Garcia-Alvarez
Speakers' Bureau - ANGELINI PHARMA ESPAÑA; Eisai Europe
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis; Advanz Pharma; Amgen; Eisai Europe; Ipsen; Pfizer
 
Sonia Serradell
No Relationships to Disclose
 
Amparo Garcia-Burillo
No Relationships to Disclose
 
Anna Casteras
No Relationships to Disclose
 
Xavier Molero
No Relationships to Disclose
 
Xavier Merino-Casabiel
No Relationships to Disclose
 
Stefania Landolfi
No Relationships to Disclose
 
Laia Blanco
No Relationships to Disclose
 
Ignacio Navales
No Relationships to Disclose
 
Iratxe Diez
No Relationships to Disclose
 
Maria Teresa Salcedo
No Relationships to Disclose
 
Marc Simo
No Relationships to Disclose
 
Jose Luis Sanchez
No Relationships to Disclose
 
Sandra Castro
No Relationships to Disclose
 
Simeon Eremiev
No Relationships to Disclose
 
Raquel Alvarez
No Relationships to Disclose
 
Anna Vazquez
No Relationships to Disclose
 
Jaume Capdevila
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Esteve; Exelixis; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sanofi
Speakers' Bureau - Bayer; Eisai; Esteve; Hutchison MediPharma; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Ipsen (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Eisai; Ipsen; Pfizer